Compare UTL & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTL | NGNE |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.9M | 744.9M |
| IPO Year | 1995 | 2014 |
| Metric | UTL | NGNE |
|---|---|---|
| Price | $53.99 | $38.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $56.50 | ★ $63.57 |
| AVG Volume (30 Days) | 80.3K | ★ 203.0K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 1.37 | 0.93 |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $536,000,000.00 | N/A |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | $4.22 | N/A |
| P/E Ratio | $25.45 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $45.17 | $15.93 |
| 52 Week High | $57.26 | $43.66 |
| Indicator | UTL | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 53.11 |
| Support Level | $49.70 | $35.26 |
| Resistance Level | $54.96 | $42.84 |
| Average True Range (ATR) | 0.96 | 2.62 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 63.22 | 40.59 |
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.